| 1 |
34387603 | Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report. | 2022 Jan 1 |
2 |
| 2 |
34799380 | As Maintenance Therapy, Olaparib's Benefits Continue. | 2022 Jan |
1 |
| 3 |
34812730 | Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. | 2022 Apr |
1 |
| 4 |
34844775 | Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain? | 2022 Feb |
4 |
| 5 |
34854226 | Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. | 2022 Apr |
1 |
| 6 |
34887522 | Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. | 2022 Apr |
1 |
| 7 |
34954029 | FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. | 2022 Jan |
3 |
| 8 |
35051747 | Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. | 2022 Feb 15 |
1 |
| 9 |
35074264 | Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. | 2022 Jun |
4 |
| 10 |
35085003 | Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review. | 2022 Jan |
1 |
| 11 |
35086955 | Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. | 2022 Apr 1 |
1 |
| 12 |
35115180 | Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. | 2022 Apr |
1 |
| 13 |
35146567 | Olaparib for ovarian cancer: a single-institution, multi-site qualitative study. | 2022 Jun |
1 |
| 14 |
35147092 | Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature. | 2022 Feb 11 |
1 |
| 15 |
35153073 | Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. | 2022 Apr |
3 |
| 16 |
35156571 | Durable Disease-Free Survival in a Patient with Metastatic Triple-Negative Breast Cancer Treated With Olaparib Monotherapy. | 2022 Feb 14 |
1 |
| 17 |
35169388 | Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. | 2022 Feb |
1 |
| 18 |
35200549 | An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer. | 2022 Jan 27 |
1 |
| 19 |
35290101 | Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. | 2022 Mar 15 |
5 |
| 20 |
35324529 | Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. | 2022 Mar 23 |
1 |
| 21 |
35357078 | Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial. | 2022 Mar 31 |
1 |
| 22 |
35444023 | Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer. | 2022 Apr 20 |
1 |
| 23 |
35511402 | PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer. | 2022 May |
1 |
| 24 |
35626017 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. | 2022 May 13 |
5 |
| 25 |
33012578 | Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. | 2021 Apr |
1 |
| 26 |
33069804 | Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib. | 2021 Feb 15 |
1 |
| 27 |
33094666 | An evaluation of olaparib for the treatment of pancreatic cancer. | 2021 Mar |
1 |
| 28 |
33236159 | PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. | 2021 Jan |
4 |
| 29 |
33250205 | Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. | 2021 Jan |
2 |
| 30 |
33268569 | Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer. | 2021 Feb |
1 |
| 31 |
33301768 | Droplet digital PCR for large genomic rearrangements detection: A promising strategy in tissue BRCA1 testing. | 2021 Feb |
1 |
| 32 |
33341987 | Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. | 2021 May |
1 |
| 33 |
33382149 | PARP inhibitors in ovarian cancer: An overview of the practice-changing trials. | 2021 May |
1 |
| 34 |
33407459 | A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report. | 2021 Jan 6 |
1 |
| 35 |
33432021 | A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients. | 2021 Jan 11 |
1 |
| 36 |
33468723 | [Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation]. | 2021 Jan |
3 |
| 37 |
33513287 | Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. | 2021 Apr |
1 |
| 38 |
33546874 | [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation]. | 2021 Feb |
1 |
| 39 |
33559413 | A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). | 2021 Mar |
3 |
| 40 |
33592660 | [Diagnostics and therapy of pancreatic carcinoma]. | 2021 Feb |
2 |
| 41 |
33617901 | Patient-derived xenograft models of BRCA-associated pancreatic cancers. | 2021 Apr |
1 |
| 42 |
33627685 | A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. | 2021 Feb 24 |
1 |
| 43 |
33637776 | BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression. | 2021 Feb 26 |
2 |
| 44 |
33662100 | Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. | 2021 May 1 |
1 |
| 45 |
33710534 | An Overview of PARP Inhibitors for the Treatment of Breast Cancer. | 2021 May |
1 |
| 46 |
33742489 | Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. | 2021 Jul |
1 |
| 47 |
33743851 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. | 2021 May |
1 |
| 48 |
33767780 | The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature. | 2021 Jan-Mar |
2 |
| 49 |
33803939 | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. | 2021 Mar 15 |
1 |
| 50 |
33827356 | Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. | 2021 Aug |
1 |